Send to

Choose Destination
Cancer Med. 2018 Aug;7(8):4132-4145. doi: 10.1002/cam4.1620. Epub 2018 Jun 21.

Validation of multiple myeloma risk stratification indices in routine clinical practice: Analysis of data from the Czech Myeloma Group Registry of Monoclonal Gammopathies.

Author information

4th Department of Medicine - Haematology, Faculty of Medicine, Charles University Hospital, Hradec Králové, Czech Republic.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Faculty of Medicine Masaryk University, Brno, Czech Republic.
1st Medical Department - Clinical Department of Haematology of the First Faculty of Medicine, General Teaching Hospital Charles University, Prague, Czech Republic.
Department of Hemato-Oncology, Faculty of Medicine and Dentistry, University Hospital Olomouc, Palacky University, Olomouc, Czech Republic.
Department of Haemato-Oncology, Faculty of Medicine, University Hospital Ostrava, University of Ostrava, Ostrava, Czech Republic.
Department of Internal Medicine and Hematology, University Hospital Kralovske Vinohrady, Prague, Czech Republic.
Hematology and Oncology Department, Charles University Hospital, Pilsen, Czech Republic.
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
Department of Hematology, Hospital Opava, Opava, Czech Republic.
Department of Hematology, Hospital Liberec, Liberec, Czech Republic.
Department of Hematology and Transfusion Medicine, Hospital Pelhrimov, Pelhrimov, Czech Republic.
Department of Clinical Haematology, Hospital in Havirov, Havirov, Czech Republic.
Department of Clinical Hematology, Hospital Ceske Budejovice, Ceske Budejovice, Czech Republic.
Department of Hematology, Hospital Novy Jicin, Novy Jicin, Czech Republic.


This study used data from the Czech Myeloma Group Registry of Monoclonal Gammopathies to validate the International Myeloma Working Group (IMWG) and revised International Staging System (R-ISS) indices for risk stratification in patients with multiple myeloma (MM) in clinical practice. Patients were included if they had symptomatic MM, complete data allowing R-ISS and IMWG staging (including cytogenetic information regarding t(4;14), t(14;16), and del(17p)), and key parameters for treatment evaluation. Median overall survival (OS) in included patients (n = 550) was 47.7 (95% CI: 39.5-55.9) and 46.2 (95% CI: 38.9-53.5) months from diagnosis and initiation of first-line therapy, respectively. Patients categorized as higher vs lower risk had reduced survival; median OS from diagnosis was 35.4 (95% CI: 30.5-40.3) vs 58.3 (95% CI: 53.8-62.9) months in high-risk vs other patients (IMWG; P = .001) and 34.1 (95% CI: 30.2-38.0) vs 47.2 (95% CI: 43.4-51.0) months in Stage III vs Stage II patients (R-ISS; P < .001). In conclusion, IMWG and R-ISS risk stratification indices are applicable to patients with MM in a real-world setting.


Czech Myeloma Group Registry; monoclonal gammopathies; multiple myeloma; overall survival; real-world; risk stratification

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center